Biography for Carly Helfand
Carly Helfand, News Editor
Carly Helfand is a news editor with Fierce's life sciences group, writing for FiercePharma, FiercePharmaMarketing and FierceVaccines. Carly got her start covering pharma while earning her master’s at Northwestern University’s Medill School of Journalism, where she concentrated in business reporting. She has completed journalism projects on four continents, and her work has appeared in various outlets such as The Boston Globe, The Washington Post’s “Wonkblog” and Cape Town’s Weekend Argus. Carly prefers watching pro hockey to nearly everything. She also plays the Irish fiddle. You can contact her at firstname.lastname@example.org and follow her on Twitter at @CarlyHFierce.
- Contact Carly
- Follow Carly on Google+
Articles by Carly Helfand
Julie Gerberding, president of Merck's vaccines unit, will be moving on come mid-December for a new role as executive vice president for strategic communications, global public policy and population health, the company announced Wednesday.
Amgen's cancer vaccine candidate may be awaiting FDA and EMA approval as a melanoma monotherapy, but like many of its peers, it's also looking to explore its prospect's potential as part of an immunotherapy duo, and now it's kicked off a trial combining its treatment with Merck's anti-PD-1 therapy that should help it do just that.
A powdered measles vaccine could mean a cheaper option for the developing world that eliminates storage, contamination and waste challenges. And researchers now have one that looks safe in Phase I.
Israel's BiondVax Pharmaceuticals, whose universal flu vaccine candidate has so far undergone a successful Phase II trial and is set for another next year, is thinking about a Wall Street IPO, according to Israeli newspaper Globes.
Just days after GlaxoSmithKline and the NIH's National Instite of Allergy and Infectious Diseases announced Phase I success for their investigative Ebola vaccine, Merck and NewLink Genetics have their own positive news to report.
After last week partially banning Novartis' Fluad, Italian officials now say tests on the flu vaccine show the product is safe.
To scale up production of its Ebola vaccine, NewLink Genetics is going to need some manufacturing help. And for that, it's turning to vaccine giant Merck.
Themis Bioscience and the Institut Pasteur have good news to report from a Phase I trial of their Chikungunya fever vaccine candidate. And the pair thinks its successful results just might lead to advances in other diseases, too.
Indian generics maker Cipla is taking its low-cost game into the vaccine field, thanks to a new deal with the Serum Institute of India.
With a brand-new $156 million Gates Foundation grant in hand, the PATH Malaria Vaccine Initiative has signed on Switzerland-based Mymetics to develop and produce virosome-based vaccine formulations for a malaria transmission-blocking vaccine candidate.